Novogenia AG, an international healthcare company specializing in human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. This launch, in collaboration with U.S. partner 10X Health, marks a significant expansion of their joint product pipeline and strengthens their international partnership in the field of genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It plays a crucial role in the processing of vitamins, neurotransmitters, and other biological molecules, influencing overall health and well-being. While standard methylation tests typically analyze a limited number of genes, MGT Plus covers 27 genes, providing a more comprehensive picture of methylation processes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health.
The broader scope of MGT Plus allows for deeper insights into methylation-related metabolic pathways, enabling healthcare providers to offer more precise and personalized prevention strategies. Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of this launch: "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies."
The timing of this launch aligns with the rapid growth of the direct-to-consumer testing market, which reached approximately $4.7 billion in 2025 and is projected to grow to over $16.0 billion by 2033. Genetic testing represents the largest segment, accounting for over 40% of the market, with North America leading globally at around 50% of market volume in 2025. This growth is driven by increasing consumer interest in personalized health information and preventive care.
Novogenia's collaboration with 10X Health underscores its commitment to making scientific innovations accessible internationally. By expanding its product portfolio with MGT Plus, Novogenia aims to actively advance personalized approaches to preventive health. The company's genetic analyses, conducted in its own laboratory, are used in disease diagnosis, treatment, and prevention, as well as in the production of tailored nutritional supplements and cosmetics. Novogenia also supports healthcare professionals by analyzing genetic predispositions to optimize patient care.
For more information about Novogenia and its products, visit Novogenia AG.
